mynth
07/2023MinorityGrowth

Lauxera invests in Organox

UNITED KINGDOM Life Sciences / Medical Devices REV £10–30M

Context

Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio. The investment thesis centers on funding the global scale-up and commercial acceleration of an established, market-leading medical device platform. OrganOx leverages a proprietary technology, normothermic machine perfusion, which has already supported over 2,500 liver transplants worldwide. The strategic rationale of the capital injection is focused on rapidly expanding OrganOx's commercial footprint and deeply institutionalizing its partnerships with tier-one transplant centers across the United States and Europe.

Organox, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

OrganOx is a UK-based company founded in 2008, originating from the University of Oxford, which markets a groundbreaking device that can keep a liver graft functional outside the human body for up to 24 hours, significantly increasing the number of grafts eligible for transplantation. With innovative technology and a dedicated team, OrganOx has become a major player in the transplantation field, with a steadily growing revenue and established profitability, having generated a profit of £7.5 million in 2024. The company provides cutting-edge solutions to improve transplantation outcomes and meet the growing needs of patients. OrganOx is a success story in the medtech sector, with a history marked by strategic partnerships and targeted investments, such as the £25 million funding round led by Lauxera in 2023, and the $142 million funding round co-led by HealthQuest and Lauxera last February.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (GBP)

Year
Rev
EBITDA
EBIT
2023
£10–30M
£0–5M
[members only]
2022
£10–30M
£0–5M
[members only]

Other operations with Organox

Other operations with Organox
DateAcquirerTargetCountrySector
08/2025TERUMOORGANOXUNITED KINGDOMMedical Devices

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
08/2023ATHOS CONSORTIUMSCHÜLKEGERMANYMedical Consumables
08/2023CARL ZEISS MEDITECD.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)NETHERLANDSMedical Devices
07/2023EQT PARTNERS / ADIADECHRA PHARMACEUTICALSUNITED KINGDOMPharma & Biotech
07/2023ELOS MEDTECHKLINGEL MEDICAL GROUPGERMANYImplants & Prosthetics
06/2023NOVO NORDISKBIOCORPFRANCEMedical Devices
04/2023INNOVAD GROUPHERBONISSWITZERLANDAnimal Health
04/2023SARTORIUSPOLYPLUSFRANCER&D Biotech
04/2023HALMAAPRIOMEDSWEDENMedical Devices
02/2023ARDIANTHERADIALFRANCEMedical Devices
01/2023DERMAPHARMARKOPHARMAFRANCENutrition & Dietary Supplements

REFERENCES

Revenue range: REV £10–30M

EBITDA range: £0–5M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Organox by Lauxera are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: organox

FAQ

What transaction does this page cover?

This page covers the acquisition of a minority stake in Organox, a British company specialised in Medical Devices, by Lauxera in 2023, structured as a growth equity investment to support its development. Ownership has since evolved, leading to a subsequent transaction with Terumo in August 2025 (see the dedicated deal page for details).

What were Organox’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Organox generated annual revenue estimated in the £10–30M range and EBITDA in the £0–5M bracket (FY 2023). Detailed financial figures are available to members.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.